Cargando…
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies. Activation of BCR signaling promotes the survival and proliferation of malignant B cells. Bruton tyrosine kinase (BTK) is a key component of BCR signaling, establishing BTK as an important therapeutic target. Sev...
Autores principales: | Gu, Danling, Tang, Hanning, Wu, Jiazhu, Li, Jianyong, Miao, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937220/ https://www.ncbi.nlm.nih.gov/pubmed/33676527 http://dx.doi.org/10.1186/s13045-021-01049-7 |
Ejemplares similares
-
Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
por: Montoya, Skye, et al.
Publicado: (2023) -
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
por: Wang, Michael L., et al.
Publicado: (2023) -
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
por: Moore, Donald C., et al.
Publicado: (2021) -
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
por: Song, Yuqin, et al.
Publicado: (2023) -
Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2018)